531 search results for “drug” in the Student website
-
Ilze Bot -
Matthias Barz -
Anne Wentink -
Stephan Hacker -
Kim Bonger -
Judy VeldhuijzenFaculty of Social and Behavioural Sciences
-
Nathaniel Martin -
Mini organs-on-chips: an alternative to drug testing on animals
Mini organs-on-chips allow us to study how diseases develop and how drugs work. Although the technology is not new, it is becoming increasingly advanced. PhD candidate Bart Kramer hopes it will eliminate animal testing in the future.
-
Spinoza Prize for chemical biologist Hermen Overkleeft
Professor of Bio-organic Chemistry Hermen Overkleeft develops innovative methods to study disease processes. This increases our understanding of the human body and enables the development of new medicines. Overkleeft has been awarded the Spinoza Prize: the most prestigious scientific award in the Ne…
-
Artificial intelligence as the co-pilot for drug discovery
There are more molecules that could conceivably be candidate drugs than there are stars in the universe. How can we ever efficiently identify those molecules? Professor of AI and Medicinal Chemistry, Gerard van Westen: ‘I’m going to use artificial intelligence as the co-pilot to make an automated search.’…
-
New potential cancer drugs and where to find them
Cancer research generates massive amounts of data, but traditional tools often fail to fully harness their potential. How can we unlock this data to provide better treatments for cancer patients? PhD candidate Marina Gorostiola González explored this by using advanced data analysis techniques to guide…
-
Hildert Bronkhorst -
Better understanding of cancer drugs – Leiden spin-off Omivera receives seed investment
How do you know if a drug will actually work? The Leiden-based spin-off Omivera is developing a new technology that could provide clearer answers. The young company received a seed investment from the investment fund UNIIQ to support its development.
-
LACDR launches training programme for innovative drug development
The Leiden Academic Centre for Drug Research (LACDR) has received a €750,000 grant from ZonMw for QPharmNL. This is a continuing education programme that trains professionals in computational techniques in pharmacology for innovative drug development.
-
Peter Bouwman -
Leiden-developed drug candidate ready for final clinical trial phase
Bringing your drug candidates to patients is what many academic chemists dream about, but the road to this goal is long and bumpy. Now, Leiden small molecule nizubaglustat is ready for phase 3 clinical trials. This is thanks to a €132 million funding secured by the biotech spin-out Azafaros.
-
market needs: new course for master’s students focuses on quality in drug development
Immediately connect with the needs of industry with your master’s degree. The new course Practical Aspects of Quality Management in Pharma and Biotech provides just that. The LACDR and LUMC set up the course together with the Biotech Training Facility, located at the Leiden Bio Science Park. The first…
-
Alexander Kros -
Laura Heitman -
Giulia Callegaro -
Arteriosclerosis and drug discovery: two young researchers win Krijn Rietveld Award for innovative research
One discovered that arteriosclerosis resembles an autoimmune disease, while the other developed a system to aid in the search for new medications. For these achievements, Marie Depuydt and Jurren de Groot were awarded the Krijn Rietveld Memorial Innovation Award on the evening of Tuesday 4 June.
-
Man-made antibodies may change the future of drug development – here’s why
Sometimes an idea seems so logical and elegant at first glance, that you later wonder why no one thought of it before. Two researchers from LACDR have teamed up to develop a completely synthetic alternative to antibodies—one that mimics their size, shape and function, but which is cheaper, more stable,…
-
Bob van de Water -
Joost Batenburg -
Gerard van Westen -
A future with tailored therapy for patients with atherosclerosis
The AtheroNeth consortium received €6 million from the Dutch Heart Foundation to gain a better understanding of the differences in disease progression among patients with atherosclerosis. The ultimate goal is to enable personalised treatment.
-
Thomas Hankemeier -
Meiling Gao -
Eline DekeysterFaculty of Social and Behavioural Sciences
-
Madeline Kavanagh -
Mario van der Stelt -
Margo Dona -
From discovery to business: 'In the lab, we often don't realise that we are working to help an immense number of patients'
'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…
-
Roxanne Kieltyka -
Rob van Wijk -
Marije Niemeijer -
From molecule to model: working together on better antibiotics
How can we combat the growing global health crisis of antibiotic resistance? At Leiden University, researchers are tackling this issue from multiple angles. PhD candidate Vladyslav Lysenko develops and redesigns new antibiotic molecules, while Sebastian Tandar studies how we can use existing antibiotics…
-
Major study offers practical guidance on antibiotic dosing in patients with obesity
Leiden researcher Anne-Grete Märtson brought together a large number of studies to better understand antibiotic dosing in patients with obesity. The publication in a renowned medical journal has already garnered much positive reactions, Märtson says. ‘It’s high time researchers started sharing more…
-
Over a million euros for two studies on solutions to antimicrobial resistance
Two consortia led by Leiden researchers have been awarded over one million euros by the Dutch Research Council and the Ministry of Health, Welfare and Sport to find solutions to antimicrobial resistance.
-
Leiden scientists join national effort to advance nanomedicine
A Dutch consortium has received €6.7 million to accelerate the development of nanomedicines together with patients. Researchers from Leiden University play a key role in the project.
-
Laura de Jong -
Leiden ‘super antibiotic’ keeps dangerous gut bacterium under control with a low dose
The antibiotic EVG7, developed in Leiden, has proven capable of fighting the dangerous gut bacterium C. difficile with only a minimal dose. What’s more, the bacterium is far less likely to return, a major issue with existing antibiotics. The research was published in Nature Communications.
-
Agreements
Read here about the various agreements in place at Leiden University for student and study associations and other student organisations.
-
Sebastian Pomplun -
Coen van Hasselt -
Anthe Janssen -
Sandra Irmisch -
Erik Danen -
How Oncode-PACT is bringing new cancer medicines closer with 325 million in Growth Fund money
How can you ensure that more experimental drugs reach the finish line? At the moment, only one in twenty cancer drugs that are tested on humans makes it to the market. This is an enormous loss for patients and society. With a grant from the National Growth Fund, Oncode-PACT aims to efficiently select…
-
Hermen Overkleeft